Of note, KRAS mutant tumor showed prominently increased TMB and remarkable clinical benefit to PD-1 inhibitors in TP53 or KRAS mutant patients, especially those with co-occurring TP53/KRAS mutations in cohorts of lung adenocarcinoma immunotherapeutic patients (48). The gene discussed is TP53; the disease is lung adenocarcinoma.